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The ABCB1 gene encodes P-glycoprotein, an ATP-dependent drug efflux pump, which is
responsible for drug transport across extra- and intra-cellular membranes.The variability in
the expression of ABCB1 may contribute to variable plasma efavirenz concentration which
results in variability in the levels of suppression of the human immunodeficiency syndrome
virus (HIV). The aim of the study was to evaluate the role of polymorphisms in ABCB1
gene on plasma efavirenz levels and treatment response in the form of change in viral
load and CD-4 cell count in HIV/AIDS patients receiving efavirenz-containing highly active
antiretroviral treatment regimens.Two hundred and eighty-two HIV-infected patients were
recruited fromThemba Lethu Clinic in Johannesburg and plasma efavirenz drug concentra-
tion levels were measured using LC-MS/MS. SNaPshot was used to genotype five known
ABCB1 single nucleotide polymorphisms (SNPs). Genotype-phenotype correlations were
computed. The ABCB1 4036A/G and 4036G/G genotypes were significantly associated
with low plasma efavirenz concentrations (P =0.0236), while the ABCB1 1236C/T and
1236T/T genotypes were associated with high efavirenz concentrations (P =0.0282). A
haplotype ABCB1T-G-T-A is reported that is associated with significantly increased plasma
efavirenz levels.This is the first report on 61A>G, 2677G>T/A, and 4036A>G SNPs in the
South African population. ABCB1 plays a role in determining the plasma concentrations of
efavirenz and should be taken into account in future design of assays for genotype-based
dosing of efavirenz-containing regimens.
Keywords:ABCB1, efavirenz, HIV/AIDS, South Africa, pharmacogenetics
INTRODUCTION
Efavirenz provides the backbone to first-line highly active anti-
retroviral treatment (HAART) in South Africa. HAART effectively
suppresses human immunodeficiency syndrome virus (HIV)
replication in the majority of patients (Mocroft et al., 2003). Thus,
many HIV-infected patients are now living longer compared to
the pre-HAART period. However, long term antiretroviral (ARV)
treatment has its own challenges such as drug–drug interactions
and the development of adverse drug reactions (ADRs). Drug–
drug interactions are a major problem in HIV/AIDS patients due
to co-morbidities such as TB and malaria.
FDA-approved ARV drugs, including efavirenz, indinavir, nel-
finavir, and ritonavir are affected by the activities of the mul-
tidrug transporter P-glycoprotein (P-gp), coded by the ABCB1
gene. ABCB1 forms part of the ATP-binding cassette gene family
with about 50 members and is located on chromosome 7q21.12,
spanning 209.6 kb, and containing 29 exons (Bodor et al., 2005).
Genetic variation in the ABCB1 gene is known to alter mRNA
stability or splicing activity (Fung and Gottesman, 2009). The
three most common single nucleotide polymorphisms (SNPs) in
the protein coding region of ABCB1 are 1236C>T (rs1128503),
3435C>T (rs1045642), and 2677G>T/A (rs2032582), where mul-
tiple alleles have been reported. The 1236C>T SNP occurring in
exon 13, does not result in an amino acid change, but may affect
ABCB1 expression through codon usage (Gu et al., 2004). The
allele frequency of 1236T variant ranges from 10% among South
Africans (Dandara et al., 2011) to 90% among Asians (Ambud-
kar et al., 1999). The 2677G>T/A SNP results in a change from
serine to alanine or threonine at residue 893, but the effect of the
changes on protein function is uncertain. The 3435T allele has
been associated with reduced expression of P-gp, although it is
synonymous (Meissner et al., 2004). Large inter-ethnic variability
has been reported for the 3435C>T SNP with the ABCB1 3435C
variant being the most frequent at 83, 58, 57, and 11% among
Africans (Kenyans and Ghanaians), Asians (Chinese), Caucasians,
and Yoruba individuals, respectively (Ameyaw et al., 2001). The
ABCB1 3435T variant has been linked with good immune recov-
ery in HIV/AIDS individuals, while the presence of the ABCB1
2677T variant has been strongly associated with virological failure
(Motsinger et al., 2006). A few studies have suggested associations
between ABCB1 gene polymorphisms and variability in plasma
efavirenz concentrations (Fellay et al., 2002; Mukonzo et al., 2009),
but all the studies lack adequate sample size. There are conflict-
ing reports on the effects of these SNPs on efavirenz treatment
response (Cascorbi et al., 2001; Fellay et al., 2002; Cascorbi, 2006).
Replication studies are thus necessary to understand the contribu-
tion of ABCB1 gene variants to plasma efavirenz levels. Dandara
et al. (2011) showed that genetic variants inABCB1 are frequent in
the South African population, and this study is a continuation fur-
ther evaluating the clinical significance of these SNPs. Therefore,
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the aim of this study was to investigate the role of genetic polymor-
phisms inABCB1 on plasma efavirenz levels in HIV/AIDS patients
in the South African population.
RESULTS
The mean age of the HIV/AIDS patients was 41.3 years, and more
than 75% (n= 227) were female. Of the patients, 7 and 10%
smoked and consumed alcohol. The clinical characteristic of the
patients included viral load and CD-4 cell count (Table 1).
COMPARISON OF ALLELE FREQUENCIES AMONGWORLD POPULATIONS
The genotypes for all the SNPs were observed in the
HIV/AIDS patients, except the ABCB1 61G/G (rs9282564) geno-
type. All ABCB1 SNPs were in Hardy–Weinberg Equilibrium
(HWE). The ABCB1 61A/G (rs9282564), 3435T/T (rs1045642),
4036G/G (rs3842), 1236T/T (rs1128503), 2677T/A, and 2677G/A
(rs2032582) genotypes were present at frequencies of 0.006,
0.024, 0.036, 0.015, 0.004, and 0.004, respectively, among the
South Africans. No individuals with an ABCB1 3435A allele was
observed in the South African cohort (Table 2), and this is sim-
ilar to what was reported by Dandara et al. (2011). The allele
frequencies of SNPs in the South Africans were compared to
the allele frequencies reported previously in other populations
(Table 2), available from previous studies or the HapMap project
(http://hapmap.ncbi.nlm.nih.gov/).
CORRELATION OF GENETIC VARIATION WITH PLASMA EFAVIRENZ
CONCENTRATION
TheABCB14036A/G and 4036G/G genotypes were associated with
significantly decreased efavirenz levels (P = 0.0236), compared to
the 4036A/A genotype (Figure 1A). Fewer individuals with the
ABCB1 4036G/G genotype changed treatment compared to the
individuals with the 4036A/A genotype (Table 3). The ABCB1
1236C/T and 1236T/T genotypes were associated with signifi-
cantly higher plasma efavirenz concentrations, compared to the
1236C/C genotype (P = 0.0282; Figure 1C). Compared to the
ABCB1 1236C/C genotype, more individuals with the 1236T/T
genotype changed antiretroviral regimens 1 year post treatment
initiation (Table 3). No difference was observed when compar-
ing individuals with efavirenz concentration above 4µg/mL to
those with concentrations below 4µg/mL, with respect to change
in treatment regimens (P = 0.571). No significant differences
were observed in efavirenz concentrations between the ABCB1
2677G>T/A and ABCB1 3435C>T genotypes (Figures 1B,D).
HAPLOTYPE ANALYSIS
Haplotype and efavirenz plasma levels for each patient are pre-
sented in supplementary Table A1. The haplotypes with respect to
1236C>T,2677G>T/A,3435C>T, and 4036A>G SNPsC-G-C-A,
C-G-C-G, C-G-T-G, T-G-C-A, T-G-T-A, T-G-T-G, T-T-T-A, and
T-T-T-G had the following frequencies in the HIV/AIDS patients;
0.67, 0.17, 0.04, 0.03, 0.06, 0.01, 0.001, and 0.01, respectively.
The ABCB1 T-G-T-A haplotype had the highest mean plasma
log10 efavirenz concentrations (0.90µg/mL) compared to 0.49 and
0.65µg/mL among patients with the T-G-C-A or T-G-T-G hap-
lotypes, respectively (Figure 2). The efavirenz concentrations dif-
fered significantly between individuals with the ABCB1 C-G-C-G
Table 1 | Clinical characteristics of the South African HIV/AIDS
patients.
Clinical characteristics HIV/AIDS patients (n=301)
Median HIV-RNA at baseline,
copies/mL±SD (range)
26917.71±27133.50 (25–98400)
Median HIV-RNA at 6 months
post-initiation of HAART,
copies/mL±SD (range)
1518.52±9004.10 (0–75000)
Average CD-4 cell count at baseline,
cells/µL±SD (range)
136.09±113.24 (2–605)
Average CD-4 cell count at 6 months
post-initiation of HAART,
cells/µL±SD (range)
261.76±137.68 (28–775)
ARV regimens
3TC_TDF_EFV 9
AZT_3TV_EFV 11
d4T_3TC_EFV 222
d4T_3TC_LPVr 18
d4T_3TC_NVP 22
Average plasma efavirenz
concentration, µg/mL (range)
4.64 (0.6–22)
andT-G-T-A haplotypes (P = 0.007) and were still significant after
Bonferroni’s correction for multiple testing (cut-off significant
P < 0.01).
UNIVARIATE AND MULTIVARIATE REGRESSION ANALYSIS OF
EFAVIRENZ CONCENTRATION
Univariate regression analysis was performed to determine the
effect of age, gender, tobacco smoking, alcohol use, BMI at baseline,
CD-4 cell count, log10 HIV-RNA levels,ABCB1haplotypes,ABCB1
1236C>T, 4036A>G, 3435C>T, and 2677G>T/A genotypes on
plasma efavirenz concentrations (Table 4). The genotypes of the
four SNPs 1236C>T, 2677G>T/A, 3435C>T, and 4036A>G sig-
nificantly predicted efavirenz concentration individually and were,
thus, included in the multivariate analysis together with age, gen-
der, tobacco smoking, alcohol use and BMI at baseline. Stepwise
backward regression analysis was then performed to identify the
minimum set of independent variables that are predictive of
plasma efavirenz levels and to determine the relative contribution
of each variable to efavirenz concentration variability. Only three
independent variables remained in the final model with P< 0.05,
including ABCB1 1236C>T (standardized regression coeffi-
cient= 0.24; P = 0.004), ABCB1 4036A>G (standardized regres-
sion coefficient= 0.17;P = 0.009), andABCB1 2677G>T/A (stan-
dardized regression coefficient= 0.36; P = 0.047). The adjusted
coefficient of determination (R2) for the regression was 0.16,
indicating that 16% of the total variance in efavirenz concentra-
tions was explained by the model. ABCB1 1236C>T, 4036A>G,
and 2677G>T/A genotypes accounted for 29, 23, and 17%
(respectively) of the total variance in plasma efavirenz concen-
trations. When repeating the multivariate analysis among female
patients only, the adjusted coefficient of determination (R2) for
the regression was 0.18, indicating that 18% of the total vari-
ance in efavirenz concentrations was explained by the model
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Table 2 | Allele frequencies in the South Africans compared to other populations.
Population Reference N 61G 1236T 3435T 2677T 2677A 4036G
Black South Africans# (Dandara et al.,
2011)/This study
979 0.003 0.090 0.120 0.040 0.004 0.202
Sotho/Tswana South Africans This study 127 0.000 0.106 0.110 0.012 0.004 0.165
Xhosa South Africans This study 107 0.014 0.178* 0.210* 0.098* 0.005 0.224
Zulu South Africans This study 139 0.000 0.119 0.140 0.022 0.000 0.209
Malawi Brown et al. (2011) 30 N/A N/A 0.210 0.000 0.000 N/A
Yoruba Hapmap 226 0.000 0.124 0.111 0.000* 0.000 0.142
Luhya Ikediobi et al. (2011) 89 N/A 0.110 N/A N/A N/A N/A
Maasai Ikediobi et al. (2011) 143 N/A 0.140 0.840* N/A N/A N/A
African-American Hapmap 46 0.000 0.136 0.071 0.077 0.000 0.000*
Caucasian Hapmap 226 0.100* 0.451* 0.571* 0.340* 0.042* 0.142
Gujarati Indian Hapmap 176 0.017 0.597* 0.597* 0.653* 0.000 0.163
Mexican Hapmap 96 0.052* 0.460* 0.460* 0.430* 0.000 0.230
Toscan Hapmap 176 0.062* 0.426* 0.466* 0.438* 0.000 0.138
Chinese Ikediobi et al. (2011) 45 0.000 0.680* 0.580* N/A N/A N/A
Japanese Hapmap 90 0.000 0.587* 0.459* 0.552* 0.000 0.320*
N/A, not available, *statistically significant difference from the frequencies among the Black South African group#.
FIGURE 1 | (A–D) ABCB1 4036A/G and G/G genotypes (P =0.0236)
are associated with reduced efavirenz levels, while 1236C/T and T/T
genotypes (P =0.0282) are associated with increased efavirenz
levels in South African HIV/AIDS patients. Only significant P -values
(without Bonferroni correction), using the dominant genetic model,
are shown.
compared to the 16% explained when males and females were
combined. However, the majority of HIV/AIDS patients in our
study were female. Further statistical analysis comparing only
the genetic- and non-genetic factors in the multivariate analysis,
showed that the genetic factors alone explained 11% of variance
in efavirenz levels, while the non-genetic factors only explained
3% compared to the 16% explained by the combined multivariate
analysis.
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Table 3 | Frequency of HIV/AIDS patients changing ART regimens within 3 months, 6 months and 1 year post-initiation of treatment*.
Genotype Treatment initiation (n) 3 months P -value 6 months P -value 1 year P -value
EFV-CONTAINING ARV REGIMEN
3TC_TDF_EFV 9 0.11 0.00 0.11
AZT_3TC_EFV 11 0.00 0.182 0.09 0.993 0.18 0.898
d4T_3TC_EFV 222 0.03 0.05 0.14
1236C/C 192 0.04 0.05 0.12
1236C/T 44 0.02 0.399 0.04 0.636 0.18 0.089
1236T/T 3 0.00 0.00 0.50
3435C/C 192 0.04 0.05 0.13
3435C/T 44 0.00 0.387 0.05 0.962 0.16 0.653
3435T/T 3 0.33 0.00 0.00
2677G/G 229 0.03 0.06 0.13
2677G/T 7 0.00 0.563 0.11 0.666 0.00 0.706
2677T/A and G/A 2 0.00 0.00 0.50
4036A/A 153 0.03 0.05 0.14
4036A/G 78 0.03 0.987 0.06 0.834 0.14 0.852
4036G/G 8 0.00 0.00 0.11
*Only 282 patients had information on treatment regimens. ABCB1 61A>G was excluded based on being monomorphic.
FIGURE 2 |The effect ofABCB1 haplotypes on plasma efavirenz
concentrations. Only significant P -values after Bonferroni’s correction for
multiple testing at significance P <0.01 are shown. The ABCB1 C-A-C-A,
C-T-C-A, and T-T-T-G haplotypes were only observed once and thus excluded
from the analysis.
CORRELATION OF GENETIC VARIATION WITH CLINICAL PARAMETERS
The average CD-4 cell count and viral load of individuals with
the different genotypes for ABCB1 1236C>T and 4036A>G were
compared at baseline and also 6 months post-initiation of ARV
therapy. The ABCB1 1236C/T and 4036G/G genotypes were asso-
ciated with the biggest decreases in viral load at 6 months (as
shown in Figures 3A,B). None of the individuals with the ABCB1
1236T/T genotype had information on viral load at baseline or
6 months post-initiation of treatment. The ABCB1 1236T allele is
associated with decreased expression of P-gp (Gow et al., 2008)
and the ABCB1 4036G allele is associated with increased expres-
sion of P-gp. However, there were no major genotype associated
differences in the recovery of the CD-4 cells with all genotypes
showing a positive response (Figures 3C,D).
DISCUSSION
HETEROGENEITY OF AFRICAN POPULATIONS IN TERMS OF GENETICS
To our knowledge, the present study is the first to report on
the allele and genotype frequencies of the ABCB1 61A>G,
2677G>T/A, and 4036A>G polymorphisms in the South African
population. However, the other SNPs have been previously
reported by Dandara et al. (2011). This data contributes to the
accumulation of information on genetic variants of pharma-
cogenetics relevance among Africans. The allele frequencies of
the genetic polymorphisms in South Africans were also com-
pared to the frequencies among other African, African-American,
Asian, and Caucasian populations (Table 2). As expected there are
significant differences in the allele frequencies between African
populations and Caucasians, for example, the allele frequency
of the ABCB1 3435T allele in African populations ranges from
0.07 to 0.12, but is present at a frequency of almost 0.6 in Cau-
casian individuals. Differences in allele frequencies between the
South African population compared with other African popula-
tions were also observed. The allele frequencies of the ABCB1
4036G, 2677T, and 2677A alleles were different to the frequencies
reported in the Yoruba individuals (P < 0.0001). The differences
in allele frequencies between the African and Caucasian individu-
als show that therapeutic drugs, including efavirenz, may not have
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Table 4 | Univariate and multivariate regression analysis of efavirenz
concentration.
Independent
variable
Log10 efavirenz,
% (95%CI)
P Contribution
in model (%)
UNIVARIATE
Age 0.01 (−0.06 to 0.08) 0.738 1.36
Gender −7.34 (−21.5 to 6.81) 0.307 0.12
Tobacco smoking −0.75 (−27.2 to 25.7) 0.956 2.60
Alcohol use −12.4 (−34.3 to 9.45) 0.263 11.9
BMI at baseline −0.70 (−2.16 to 0.76) 0.344 15.2
CD-4 cell count at
baseline
0.01 (−0.06 to 0.07) 0.793 –
CD-4 cell count at
6 months
−0.04 (−0.09 to 0.02) 0.186 –
Log10 HIV-RNA at
baseline
−11.9 (−21.3 to −2.44) 0.015 –
Log10 HIV-RNA at
6 months
10.4 (−7.26 to 28.0) 0.245 –
Genotype
(dominant model)
WT/WT Ref
ABCB1 1236C>T 18.6 (2.02 to 35.2) 0.028 28.9
ABCB1 4036A>G −14.8 (−27.5 to −2.01) 0.024 23.2
ABCB1 3435C>T 12.3 (−3.90 to 28.4) 0.136 0.12
ABCB1 2677G>T/A −30.0 (−66.4 to 6.47) 0.106 16.6
ABCB1 haplotypes 0.19 (−1.98 to 2.37) 0.862 –
MULTIVARIATE#
ABCB1 1236C>T 24.2 (7.81 to 40.6) 0.004 –
ABCB1 4036A>G −16.6 (−29.1 to −4.15) 0.009 –
ABCB1 2677G>T/A −35.9 (−71.3 to −0.43) 0.047 –
#Only significant covariates in the multivariate regression analysis are shown.
similar effectiveness in different populations when given at stan-
dard dosages. Similarly, fine scale genetic structure exists within
the African population which, therefore, should not be treated as
one population.
IMPLICATIONS FOR DISEASE OR DRUG TREATMENT AND POSSIBLE
DEVELOPMENT OF DIAGNOSTIC TOOLS
We observed lower plasma efavirenz concentrations among indi-
viduals with theABCB1 4036A/G and 4036G/G genotypes and this
could perhaps be as a result of the disruption of a miRNA bind-
ing site in the 3′UTR of ABCB1. Five poorly conserved miRNAs
namely; miR-129, miR-491, miR-4795, miR-561, and miR-4717
have been predicted to target the 3′UTR region surrounding the
ABCB1 4036A>G SNP using the TargetScanHuman 6.1 miRNA
target prediction software. Disruption of these sites could poten-
tially cause reduced transport of efavirenz by ABCB1 resulting in
lower plasma efavirenz levels. In a different study among Ugan-
dans, theABCB14036A/G and 4036G/G genotypes were associated
with higher efavirenz bioavailability (Mukonzo et al., 2009). In the
current study,ABCB1 1236C/T and 1236T/T genotypes were asso-
ciated with high plasma efavirenz concentrations, but there are
conflicting reports on the effect of ABCB1 1236C>T genotypes
in tacrolimus, cyclosporine, and sirolimus drug responses (Kuzuya
et al., 2003; Anglicheau et al., 2004; Haufroid et al., 2004), making it
difficult to draw conclusions. There are conflicting reports as well
for the role or effects of ABCB1 2677G>T/A and 3435C>T poly-
morphisms (Schwab et al., 2003; Leschziner et al., 2007). Haas et al.
(2005) reported an association between theABCB1 3435T/T geno-
type and a decreased likelihood of virologic failure and decreased
resistance to efavirenz, but not with plasma efavirenz exposure.
Clinical parameters such as CD-4 cell count, viral load, disease
stage, hemoglobin, AST, and ALT levels were used as indicators
of ARV treatment efficacy, underlying liver disease and disease
progression in the HIV/AIDS patients. As expected, efavirenz-
containing HAART led to a general (48%) increase in CD-4 cell
count (cells/µL) and a 94% decrease in viral load (copies/mL)
when baseline levels where compared to levels at 6 months post-
initiation of treatment. Failure of reduction in viral load and
emergence of opportunistic infections after 6 months led to ARV
switching. Sustained viral load after 6 months and the presence
of opportunistic infections are indications of possible treatment
failure or non-adherence. On the other hand, other studies have
shown that high plasma efavirenz concentrations are associated
with development of adverse drug events leading to drug discon-
tinuation (Marzolini et al., 2001; Lubomirov et al., 2011; Wyen
et al., 2011).
CONCLUSION
The current study showed that the drug transporter ABCB1 con-
tributes in predicting response to efavirenz treatment in the
South African HIV/AIDS population. The ABCB1 4036A>G and
1236C>T polymorphisms were significantly correlated with low
and high plasma efavirenz concentration levels, respectively. How-
ever, this data should be taken together with the variation in
CYP2B6 which has a profound effect on efavirenz metabolism. The
CYP2B6 516G>T SNP is known to be associated with high plasma
efavirenz levels and the combined effect of CYP2B6 together with
ABCB1 SNPs will be more informative in predicting response to
efavirenz treatment. This strongly supports the development of a
pharmacogenetic suite of gene variants to assist in deciding the
HAART regimen for HIV/AIDS treatment in a clinical setting as
well as the starting ARV dosage.
MATERIALS AND METHODS
RESEARCH PARTICIPANTS
All participants provided written informed consent and study
approval was obtained from the University of Cape Town Health
Science Faculty Research Ethics Committee, Cape Town, South
Africa and the University of Witwatersrand Human Research
Ethics Committee, Gauteng, South Africa. The research was per-
formed in accordance with the guidelines of the Helsinki Declara-
tion of 2008. Two hundred and eighty-two (n= 282) South African
HIV/AIDS patients receiving efavirenz-based treatment for at least
6 months, were recruited to participate in this study. All sub-
jects were of Bantu origin and comprised of Sotho/Tswana from
Gauteng and Xhosa subjects from the Western Cape Province,
South Africa. All subjects gave information on their ethnicity, age,
health status (including self-reported adherence to treatment or
pill counts), dietary, and smoking habits.
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FIGURE 3 | (A–D) The effect of ABCB1 4036A>G and 1236C>T on average HIV-RNA and CD-4 cell count at baseline and 6 months post-initiation of treatment.
A 5 mL whole blood sample was obtained from each subject,
and used for plasma sample collection as well as DNA extrac-
tion. DNA was isolated using a salting-out method adapted from
Gustafson et al. (1987) or the GenElute™ Blood Genomic DNA
Kit (Sigma-Aldrich, St. Louis, MO, USA). Steady-state plasma
samples were available for 137 HIV/AIDS patients 12–16 h post
dose with efavirenz. Plasma efavirenz concentrations were deter-
mined by LC/MS/MS (API 4000 triple quadrupole MS/MS Applied
Biosystems, South Africa) according to the method by Chi et al.
(2002).
SELECTION OF SNPs AND GENOTYPING METHODS USED
Five previously reported SNPs in ABCB1 [GenBank acces-
sion: NM_000927.4], namely 61A>G, 1236C>T, 2677G>T/A,
3435C>T, and 4036A>G were selected for investigation based
on having minor allele frequencies above 10% in the African-
Americans, South African, or other African populations and were
genotyped using SNaPshot mini-sequencing (Table 5).
Each PCR reaction contained, 50 ng of genomic DNA, 1X Green
GoTaq Flexi Reaction Buffer (Promega Corporation, Madison,
WI, USA), 0.2 mM of each of the deoxynucleotide triphosphates
(dNTPs; Bioline, London, UK); 1.5 mM MgCl2 (Promega Corpo-
ration, Madison, WI, USA); 40 pmol of the forward and reverse
primers (Integrated DNA Technologies, Inc., Coralville, IA, USA);
1 U of GoTaq Flexi DNA Polymerase (Promega Corporation,
Madison, WI, USA). The PCR reactions were carried out using
a “MyCycler Thermal cycler” from Bio-Rad. PCR conditions were
as follows: 3 min at 94˚C; 40 cycles of 94˚C for 30 s, the annealing
temperature specific to each SNP for 30 s, 72˚C for 50 s; and 10 min
at 72˚C for final extension.
Five microliters of each PCR product was pooled and 10µL of
the combined PCR products were cleaned using 1.5 U shrimp alka-
line phosphatase (Fermentas Life Sciences, Burlington, Canada)
and 2 U ExoI (Fermentas Life Sciences, Burlington, Canada) in
a total reaction volume of 20µL. The shrimp alkaline phos-
phatase and ExoI reaction was incubated at 37˚C for 1 h and
the enzymes were inactivated at 75˚C for 15 min. SNaPshot sin-
gle base extension of the genetic polymorphisms was performed
on the “GeneAmp® PCR System 9700 version 3.08′′ (Applied
Biosystems, Carlsbad, CA, USA) using the SNaPshot cycling pro-
gramme as 96˚C for 10 s, and then repeated for 25 cycles at
50˚C for 5 s and 60˚C for 30 s. The SNaPshot reaction (10µL)
contained 1µL ABI Prism® SNaPshot™ Multiplex Kit (Applied
Biosystems, CA, USA) and the pooled internal SNaPshot primers
(Integrated DNA Technologies, Inc., Coralville, IA, USA). Follow-
ing the SNaPshot reaction, the clean-up reaction was repeated
using 1 U shrimp alkaline phosphatase using cycling conditions
as mentioned before, and capillary electrophoresis was performed
using a ABI 3130xl Genetic Analyzer (Applied Biosystems, Carls-
bad, CA, USA). SNaPshot results were analyzed on the Gen-
eMapper © Software version 4.1 (Applied Biosystems, Carlsbad,
CA, USA).
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Table 5 | PCR and SNaPshot amplification conditions forABCB1 SNPs (GenBank accession: NM_000927.4).
SNP Primer sequence (5′-3′) Ta (˚C) PCR product References
4036A>G F: CCTCAGTCAAGTTCAGAGTCTTCA 54˚C 297 Designed
R: TCACAGGCAGTTGGACAAG
SNaPshot primer: TCTTGGCAGAAACTGCAAAAGGAGATTGAT
3435C>T F: ACTCTTGTTTTCAGCTGCTTG 54˚C 230 Rhodes et al.
(2007)R: AGAGACTTACATTAGGCAGTGACTC
SNaPshot primer: ACTCGTCCTGGTAGATCTTGAAGGG
2677G>T/A F: ATGGTTGGCAACTAACACTGTTA 54˚C 206 Rhodes et al.
(2007)R: AGCAGTAGGGAGTAACAAAATAACA
SNaPshot primer: CTTCGACCTAAGTGGAGAATGAGTTATTCTAAGGA
1236C>T F: TGTGTCTGTGAATTGCCTTGAAG 51˚C 228 Rhodes et al.
(2007)R: CCTCTGCATCAGCTGGACTGT
SNaPshot primer: TTAATTAATCAATCATATTTAGTTTGACTCACCTTCCCAG
61A>G F: CTGCGGTTTCTCTTCAGGTC 51˚C 149 Designed
R: GATTCCAAAGGCTAGCTTGC
SNaPshot primer: CTCCTTTGCTGCCCTCAC
STATISTICAL ANALYSIS
Statistical analysis was performed using the Graphpad Prism (Ver-
sion 5, GraphPad Software Inc., San Diego, CA) and STATA
(Version 11, StatSoft, USA) statistical programs. ABCB1 hap-
lotypes were inferred using Phase v2.1 (Stephens et al., 2001;
Stephens and Donnelly, 2003; Stephens and Scheet, 2005). Pear-
son’s χ2-test and Fisher’s exact test were used to compare the
allele frequencies to results previously published in populations
of different ethnicity. Fisher’s exact test was also used to com-
pare change in treatment regimen between the ABCB1 genotypes.
One-way analysis of variance, followed by Bonferroni’s multiple
comparison tests, was used to determine the effect of ABCB1
haplotypes on plasma log10 efavirenz levels. Genotypes were
dichotomized according to the dominant genetic model (wild-
type= 0 and heterozygote/homozygote variants= 1). Univariate
regression analysis was applied to log10 efavirenz concentrations
as dependant variable and the percentage change in efavirenz
levels, with the 95% CI, was calculated as 100× regression coef-
ficient. Multivariate regression analysis was performed by includ-
ing covariates from the univariate analysis, followed by stepwise
backward removal. TargetScanHuman 6.1 miRNA target pre-
diction software were used to predict miRNA binding to the
ABCB1 3′UTR. The following equation was used to calculate
the sample size required to achieve a 99% confidence-interval:
N = [DEFF ∗ Np(1−p)]/[(d2/Z21−α/2 ∗ (N−1) + p ∗ (1−p)].
DEFF is defined as the design effect, Z is the value for 99% confi-
dence,d is anα-value= 0.05, while p is the frequency of the variant
allele. A DEFF-value of 1 was used for random sampling, aZ -value
of 1.96 and allele frequency of 0.1 was used to calculate the sample
size of N = 239 samples. All statistical tests were performed two
tailed, and statistical significance was defined as P< 0.05.
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APPENDIX
Table A1 |ABCB1 haplotype composition for each HIV/AIDS patient
where steady-state plasma efavirenz levels were available.
HIV/AIDS
patients
ABCB1 haplotype
combination*
Log10 efavirenz
levels (µg/mL)
1 C-G-C-A/C-G-C-A 0.111
2 C-G-C-A/C-G-C-A 0.838
3 C-G-C-A/C-G-T-A 0.023
4 C-G-C-A/C-G-C-A −0.013
5 C-G-C-A/C-G-C-A 0.676
6 C-G-C-A/C-G-C-G 0.507
7 C-G-C-A/C-G-T-A 0.275
8 C-G-C-A/C-G-C-G 0.199
9 C-G-C-A/C-G-C-G 0.428
10 C-G-C-A/C-G-C-G 0.327
11 C-G-C-A/C-G-T-A −0.229
12 C-G-C-A/C-G-C-G 0.917
13 C-G-C-A/C-G-C-G 0.208
14 C-G-C-A/C-G-C-G 0.415
15 C-G-C-A/C-G-C-G 0.478
16 C-G-C-A/C-G-C-A 0.321
17 C-G-C-A/C-G-C-G 0.276
18 C-G-C-A/T-G-T-A 0.624
19 C-G-C-A/C-G-T-A 1.083
20 C-G-C-A/C-G-C-G 0.170
21 C-G-C-A/C-G-C-G 0.445
22 C-G-C-A/C-G-T-A 0.611
23 C-G-C-A/C-G-C-G 0.419
24 C-G-C-A/C-G-C-G 0.558
25 C-G-C-A/C-G-C-A 0.622
26 C-G-C-A/C-G-C-A 0.267
27 C-G-C-G/C-G-C-G 0.107
28 C-G-C-A/T-G-T-G 1.170
29 C-G-C-A/C-G-C-A 0.083
30 C-G-C-A/C-G-C-A 0.390
31 C-G-C-A/C-G-C-A 0.408
32 C-G-C-A/C-G-C-A 0.720
33 C-G-C-A/C-G-C-A 0.378
34 C-G-C-A/C-G-T-A 0.157
35 C-G-C-A/C-G-C-G 0.172
36 C-G-C-A/C-G-C-A 0.029
37 C-G-C-A/C-G-C-A 0.902
38 C-G-C-A/C-G-C-A 0.380
39 C-G-C-A/C-G-C-A 1.016
40 C-G-C-A/C-G-C-A 0.880
41 C-G-C-A/T-G-C-A 0.407
42 C-G-C-A/C-G-C-G 0.819
43 C-G-C-A/C-G-C-A 0.780
44 C-G-C-A/C-G-C-A 1.316
45 C-G-C-A/C-G-C-G 0.112
46 C-G-C-G/T-G-C-A 0.554
47 C-G-C-A/C-G-C-G 0.419
48 C-G-C-A/C-G-C-A 0.352
49 C-G-C-A/C-G-C-A 1.141
50 C-G-C-A/T-T-T-G 0.539
(Continued)
HIV/AIDS
patients
ABCB1 haplotype
combination*
Log10 efavirenz
levels (µg/mL)
51 C-G-C-A/T-G-T-A 1.303
52 C-G-C-A/C-G-C-A 0.927
53 C-G-C-A/C-G-C-G 0.298
54 C-G-C-A/C-G-C-G 0.892
55 C-G-C-A/C-G-C-A 0.422
56 C-G-C-A/T-G-T-G 0.899
57 C-G-C-A/T-G-C-A 0.428
58 C-G-C-G/C-G-C-G 0.723
59 C-G-C-A/T-T-T-G 0.205
60 C-G-C-A/C-G-C-A 0.353
61 C-G-C-A/C-G-C-G 0.252
62 C-G-C-G/C-G-C-G 0.499
63 C-G-C-A/C-G-C-A 0.442
64 C-G-C-A/T-G-T-G 0.095
65 C-G-C-A/C-G-C-A 0.649
66 C-G-C-G/T-G-C-A 0.405
67 C-G-C-A/C-G-C-A 0.495
68 C-G-C-A/C-G-C-G 0.413
69 C-G-C-A/C-G-C-A 0.619
70 C-G-C-A/C-G-C-A 0.196
71 C-G-C-A/T-G-T-A 1.306
72 C-G-C-A/C-G-C-G 0.328
73 C-G-C-A/C-G-C-A 0.932
74 C-G-C-A/C-G-C-A 0.315
75 C-G-C-A/C-G-C-A 1.322
76 C-G-C-A/C-G-C-A 0.585
77 C-G-C-A/C-G-C-A 0.623
78 C-G-C-G/C-G-T-A 0.215
79 C-G-C-A/C-G-C-A 1.125
80 C-G-C-A/C-G-C-A 0.294
81 C-G-C-A/T-G-T-G 0.947
82 C-G-C-A/T-G-T-A 1.160
83 C-G-C-A/C-G-C-A 0.989
84 C-G-C-A/C-G-C-A 0.072
85 C-G-C-A/C-G-C-A 0.415
86 C-G-C-A/C-G-C-A 0.214
87 C-G-C-A/C-G-C-A 0.874
88 C-G-C-A/C-G-C-G 0.450
89 C-G-C-A/C-G-C-A −0.140
90 C-G-C-A/C-G-T-A 1.037
91 C-G-C-A/C-G-C-A 0.381
92 C-G-C-A/C-G-C-A −0.143
93 C-G-C-A/C-G-C-G 0.076
94 C-G-C-A/C-G-C-G 0.924
95 C-G-C-A/C-G-C-G 0.033
96 C-G-C-A/C-G-C-A 0.946
97 C-G-C-A/C-G-C-A −0.164
98 C-G-C-G/T-G-C-A −0.029
99 C-G-C-A/C-G-C-A −0.105
100 C-G-C-A/C-G-C-A 0.645
(Continued)
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Table A1 | Continued
HIV/AIDS
patients
ABCB1 haplotype
combination*
Log10 efavirenz
levels (µg/mL)
101 C-G-C-A/C-G-C-A 0.911
102 C-G-C-A/C-G-C-G 0.394
103 C-G-C-A/T-G-T-G 0.274
104 C-G-C-A/C-G-C-G 0.313
105 C-G-C-A/C-G-C-G 0.164
106 C-G-C-A/C-G-T-A 0.371
107 C-G-C-A/C-G-C-A 0.264
108 C-G-C-A/C-T-C-A 0.010
109 C-G-C-A/C-G-C-G 0.111
110 C-G-C-A/C-G-C-A 1.109
111 C-G-C-A/C-G-C-A 0.671
112 C-G-C-A/C-G-C-A 0.324
113 C-G-C-A/C-G-C-A 0.431
114 C-G-C-A/T-G-C-A 0.431
115 C-G-C-A/C-G-C-A 0.566
116 C-G-C-A/C-G-C-A 0.780
117 C-G-C-A/T-G-T-G 0.516
118 C-G-C-A/C-G-C-G 0.276
119 T-G-C-A/T-G-T-A 0.541
120 C-G-C-A/C-G-C-A 0.821
121 C-G-C-A/T-G-T-A 1.038
122 C-G-C-A/C-G-C-A 0.364
123 C-G-C-A/C-G-C-A 1.106
124 C-G-C-A/C-G-C-A 0.584
125 C-G-C-A/C-G-C-A 1.093
126 C-G-C-A/C-G-C-A 0.692
127 C-G-C-A/C-G-C-G 0.340
128 C-G-C-A/C-G-C-A 0.751
129 C-G-C-A/C-G-C-A 0.192
130 C-A-C-A/C-G-C-A 0.092
131 C-G-C-A/C-G-C-A 0.192
132 C-G-C-A/C-G-C-A 0.106
133 C-G-C-A/C-G-C-A 0.941
134 C-G-C-A/C-G-C-A 0.204
135 C-G-C-A/T-G-C-A 1.348
136 T-G-C-A/T-G-T-A 0.329
137 C-G-C-A/C-G-C-G 0.271
*ABCB1 haplotypes with respect to 1236C>T-2677G>T/A-3435C>T-4036A>G,
61A>G was excluded from the haplotype based on being monomorphic.
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